Compared to Estimates, DexCom (DXCM) Q2 Earnings: A Look at Key Metrics
Werte in diesem Artikel
For the quarter ended June 2025, DexCom (DXCM) reported revenue of $1.16 billion, up 15.2% over the same period last year. EPS came in at $0.48, compared to $0.43 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.12 billion, representing a surprise of +3.06%. The company delivered an EPS surprise of +6.67%, with the consensus EPS estimate being $0.45.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how DexCom performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Revenue- United States: $841 million versus the six-analyst average estimate of $809.7 million. The reported number represents a year-over-year change of +14.9%.Revenue- International: $316.1 million versus the six-analyst average estimate of $311.29 million. The reported number represents a year-over-year change of +16%.Revenue- Hardware: $39.3 million versus the three-analyst average estimate of $38.99 million. The reported number represents a year-over-year change of -31.4%.Revenue- Sensor and other: $1.12 billion versus $1.08 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +18% change.View all Key Company Metrics for DexCom here>>>Shares of DexCom have returned +6.9% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.#1 Semiconductor Stock to Buy (Not NVDA)The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: DexCom und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf DexCom
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf DexCom
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu DexCom Inc.
Analysen zu DexCom Inc.
Datum | Rating | Analyst | |
---|---|---|---|
02.08.2018 | DexCom Buy | Canaccord Adams | |
03.05.2018 | DexCom Buy | Canaccord Adams | |
23.03.2018 | DexCom Outperform | Robert W. Baird & Co. Incorporated | |
28.09.2017 | DexCom Outperform | Wedbush Morgan Securities Inc. | |
15.09.2017 | DexCom Equal Weight | Barclays Capital |
Datum | Rating | Analyst | |
---|---|---|---|
02.08.2018 | DexCom Buy | Canaccord Adams | |
03.05.2018 | DexCom Buy | Canaccord Adams | |
23.03.2018 | DexCom Outperform | Robert W. Baird & Co. Incorporated | |
28.09.2017 | DexCom Outperform | Wedbush Morgan Securities Inc. | |
03.05.2017 | DexCom Buy | Canaccord Adams |
Datum | Rating | Analyst | |
---|---|---|---|
15.09.2017 | DexCom Equal Weight | Barclays Capital | |
30.04.2015 | DexCom Perform | Oppenheimer & Co. Inc. | |
27.01.2015 | DexCom Perform | Oppenheimer & Co. Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für DexCom Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen